Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials

Main Article Content

K Reich
Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

A Blauvelt
Oregon Medical Research Center, Portland, Oregon, USA

M Lebwohl
Icahn School of Medicine at Mount Sinai, New York, New York, USA

KA Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

P Rich
Oregon Dermatology and Research Center, Portland, Oregon, USA

B Strober
Yale University, New Haven, Connecticut, USA; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA

D De Cuyper
UCB Pharma, Brussels, Belgium

C Madden
UCB Pharma, Raleigh, North Carolina, USA

L Peterson
UCB Pharma, Raleigh, North Carolina, USA

V Vanvoorden
UCB Pharma, Brussels, Belgium

RB Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Keywords

Plaque Psoriasis, Biologic, Bimekizumab, Safety

Abstract

Abstract not available.

References

1. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

2. Papp KA. J Am Acad Dermatol 2018;79:277–86 e10.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.21

Article Details

How to Cite
[1]
Reich, K., Blauvelt, A., Lebwohl, M., Papp, K., Rich, P., Strober, B., De Cuyper, D., Madden, C., Peterson, L., Vanvoorden, V. and Warren, R. 2021. Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s21. DOI:https://doi.org/10.25251/skin.5.supp.21.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>